Overview

Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma

Status:
Completed

Trial end date:
2013-12-01

Target enrollment:

Participant gender:

Summary

The aim of the study is to evaluate efficacy and safety of a 48-week treatment with two doses of tiotropium bromide compared to placebo in adolescent patients with moderate persistent asthma. Efficacy and safety will be assessed by measuring lung function parameters and evaluating the effects on asthma exacerbations, on Quality of life, on health care resource utilisation an on the number of adverse events.

Phase:

Phase 3

Details

Lead Sponsor:

Boehringer Ingelheim

Collaborator:

Pfizer

Treatments:

Tiotropium Bromide